# Han Lim

> Han Lim is the Chief Business Officer of DeepCure, a Boston-based company building an end-to-end automated platform for small molecule drug discovery that pairs AI with a virtual library of a quintillion synthesizable compounds, robotic synthesis, and automated assays. A physician-scientist by training, he holds a medical degree from the University of Queensland, a PhD from the University of Cambridge, and did postdoctoral physics research at MIT before spending roughly a decade on the UC Berkeley faculty running a lab in systems biology and bioengineering. He helped build the first generation of AI drug discovery companies as Chief Business Officer at Atomwise, where he launched the internal pipeline, raised $168M across two rounds, and signed partners including Eli Lilly and Charles River Laboratories. He now leads business development, portfolio planning, and corporate strategy at DeepCure.

- **Role:** Chief Business Officer at DeepCure
- **Organizations:** DeepCure, Atomwise, University of California, Berkeley
- **Nationality:** United States
- **Education:** Medical degree (MD), University of Queensland, PhD, University of Cambridge, Postdoctoral researcher, Department of Physics, Massachusetts Institute of Technology (MIT)
- **Known for:** Raised $168M across two financing rounds while CBO at Atomwise, Secured AI drug discovery partnerships with Eli Lilly and Charles River Laboratories, Established a global program of more than 500 academic research projects at Atomwise

## Career timeline

- **Postdoc** — Postdoctoral researcher in the Department of Physics at MIT
- **~10 years** — Faculty member at UC Berkeley running a lab focused on systems biology and bioengineering
- **pre-2022** — Chief Business Officer at Atomwise; launched internal drug discovery pipeline, raised $168M across two rounds, signed Eli Lilly and Charles River Laboratories, built 500+ academic research program
- **2022** — Appointed Chief Business Officer at DeepCure (April 26, 2022)
- **2024** — DeepCure closes $24.6M Series A-1 led by IAG Capital Partners (April 2024); company has raised $72M+ total

## Achievements

- Raised $168M across two financing rounds while CBO at Atomwise
- Secured AI drug discovery partnerships with Eli Lilly and Charles River Laboratories
- Established a global program of more than 500 academic research projects at Atomwise
- Launched Atomwise's internal drug discovery pipeline
- Spent roughly a decade on the UC Berkeley faculty leading a systems biology and bioengineering lab
- Published in Nature, Nature Genetics, and PNAS

## Latest updates

- **2024-04** — DeepCure closed a $24.6M Series A-1 financing led by IAG Capital Partners to advance its immunology and inflammation pipeline toward clinical trials.

## Links

- Website: https://deepcure.com
- LinkedIn: http://www.linkedin.com/in/lim-han

---

Profile page: https://yespress.io/han-lim
Published by YesPress — https://yespress.io
Last updated: 2026-06-12